D-tek s.a. of Mons at MEDICA 2019 in Düsseldorf -- COMPAMED Trade Fair

D-tek s.a.

Parc Initialis, Rue René Descartes, 19, 7000 Mons
Belgium
Telephone +32 65 841888
Fax +32 65 842663
info@d-tek.be

This company is co-exhibitor of
AWEX - Wallonia Export & Investment

Hall map

MEDICA 2019 hall map (Hall 1): stand F53

Fairground map

MEDICA 2019 fairground map: Hall 1

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Our products

Product category: Immuno assay testing

Blue Diver Combi

BlueDiver Combi kits contain a dispenser of 24 nitrocellulose chips on which a specific antigen has been coated in a microdot-shaped format. In addition to the antigen, 2 built-in controls have been also coated on each chip. The antigens and controls are coated in triplicate spotting to ensure the quality and the validity of the results. The test is based on a classical Enzyme ImmunoAssays (EIA).

The user can select (out of more than 50 different antigens) and combine antigen chips (up to 6) to create his own immunodot test. The BlueDiver Combi offers then a complete flexibility and customization to end-users.

The BlueDiver Combi kits are automated on the BlueDiver Instrument. The complete processing time lasts just 1 hour. The semi-quantitative results can be obtained thanks to the BlueScan scanner and the Dr DOT software (minimum version 4).

Key characteristics
Indication : Suitable for small to high throughput laboratories or hospitals
Support of reaction : nitrocellulose (chip)
Volume of sample needed : 10 µl
Number of autoantibodies detected : 1 per chip, up to 6 per strip holder
Test duration : 1h
Testing : BlueDiver Instrument
Reading : BlueScan + Dr DOT software (minimum version 4)
Results : Semi-quantitative
Controls : Positive and negative built-in controls

More Less

Product category: Immuno assay testing

Blue Dot

BlueDot kits are composed of 24 nitrocellulose strips on which the antigens have been coated in a dot-shaped format. One strip allows the testing of one patient for many different autoantibodies in the same run. The test is based on a classical Enzyme ImmunoAssays (EIA).

In addition to the antigens, each strip possesses two built-in reactive controls :

The first one, the Reaction Control (RC), controls the validity of the test : its coloration proves that the clinician has added the patient serum and that the test has functioned correctly.
The second one, the Cut-Off Control (CO), allows the interpretation of the test : any color intensity equal to or below that of the cut-off is considered negative, any color intensity superior to that of the cut-off is considered positive.

The results can be interpretated by sight or a semi-quantification can be obtained thanks to the Dr DOT software.

Key characteristics
Indication : Suitable for small to high throughput laboratories or hospitals
Support of reaction : nitrocellulose (strip)
Volume of sample needed : 10 µl
Number of autoantibodies detected : up to 12
Test duration : 1h30
Testing : Manual or Open systems
Reading : Visual or Dr DOT software
Results : Qualitative or semi-quantitative
Controls : Positive and negative built-in controls

More Less

Product category: Immuno assay testing

Blue Diver Quantrix

BlueDiver Quantrix kits are composed of 24 nitrocellulose strips on which the antigens have been coated in a microdot-shaped format. All the antigens and controls are coated in triplicate spotting to ensure the quality and the validity of the results. The test is based on a classical Enzyme ImmunoAssays (EIA).

Thanks to a 6 point built-in calibration curve including blank measurement, all the results obtained are fully quantitative. BlueDiver Quantrix strips are automated on the BlueDiver Instrument and all quantitative results are obtained with the Dr DOT software.
Its format and the number of autoantibodies tested per run makes BlueDiver Quantrix the ideal complement to ANA and Hep2 screening techniques. Moreover, a complete set of built-in controls safely validates the whole process of the test (from the sample loading, the conjugate specificity/reactivity and the substrate kinetics) and meets laboratory accreditation requirements.

Key characteristics
Indication : Suitable for small to high throughput laboratories or hospitals
Support of reaction : nitrocellulose (strip)
Volume of sample needed : 10 µl
Number of autoantibodies detected : up to 25
Test duration : 1h
Testing : BlueDiver Instrument
Reading : BlueScan + Dr DOT software (minimum version 3)
Results : Quantitative
Controls : Positive, negative, conjugate, substrate built-in controls and calibration curve

More Less

About us

Company details

D-tek s.a. is a private Belgian biotechnology company created in 1995 in Mons (40 km from Brussels and less than 1h20 from Paris).

The company is located in 1.200 square meters facilities in the Scientific Park Initialis of Mons. The company is specialized in the development and manufacturing of diagnostic kits for human autoimmune diseases.

Autoimmune diseases
Autoimmune diseases are due to inappropriate immune response against the organism’s own antigens (autoantigens), leading to chronic inflammation, tissue destruction and/or dysfunction. Generally unknown by the public and perceived as uncommon, they represent nevertheless the third cause of clinical mortality in industrialized countries.

Doctors generally distinguish systemic and organ-specific autoimmune diseases, depending if they affect multiple organs or only one organ specifically. The etiology of autoimmune diseases is clearly multifactorial. Both intrinsic factors (e.g. genetics, hormones, age) and environmental factors (e.g. infections, diet, drugs, and environmental chemicals) may contribute to the induction, development and progression of autoimmune diseases.

According to the estimation of the World Health Organization, they affect up to 6 % of the global population. Scientists and doctors agree that more than 60 diseases have a proven or strongly suspected autoimmune cause. Moreover, there is epidemiological evidence of increasing prevalence of certain autoimmune diseases, which cannot be attributed to focus on or improvement of the diagnosis alone.

As the autoimmune diseases are generally incurable and require a lifelong treatment they have a strong impact on public health cost. Their accurate diagnosis has therefore become of major importance these last decades. All the diagnosis techniques available on the market are based on the ability to detect the presence of autoantibodies in the patient’s serum.

 

More Less